An update on MRD assessment and novel techniques used in the treatment of hematological malignancies

An update on MRD assessment and novel techniques used in the treatment of hematological malignancies

MRD Evaluation in Hematological NeoplasmSee more

MRD Evaluation in Hematological Neoplasm

Novel methods to assess the effectiveness of chemotherapy in AML patients: MRDSee more

Novel methods to assess the effectiveness of chemotherapy in AML patients: MRD

Assessing MRD in hematologic malignanciesSee more

Assessing MRD in hematologic malignancies

Chronic Lymphocytic Leukemia: MRD UpdatesSee more

Chronic Lymphocytic Leukemia: MRD Updates

Dr. Daver Discusses Use of MRD Assessment in Hematologic MalignanciesSee more

Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

Updated FDA MRD guidelines for hematological malignanciesSee more

Updated FDA MRD guidelines for hematological malignancies

Novel allo-CART therapies and their role in the treatment of hematological malignanciesSee more

Novel allo-CART therapies and their role in the treatment of hematological malignancies

Game-Changing Potential of MRD in Hematological Malignancies: Overview and ImportanceSee more

Game-Changing Potential of MRD in Hematological Malignancies: Overview and Importance

Novel techniques being used for MRD assessment in AML & the importance of considering oligoclonalitySee more

Novel techniques being used for MRD assessment in AML & the importance of considering oligoclonality

Measurable Residual Disease (MRD) in AML and ALLSee more

Measurable Residual Disease (MRD) in AML and ALL

MRD in Acute Myeloid LeukemiaSee more

MRD in Acute Myeloid Leukemia

MRD in AML: What is it and what do I do about it?See more

MRD in AML: What is it and what do I do about it?

What is MRD and why is it important in acute myeloid leukemia?See more

What is MRD and why is it important in acute myeloid leukemia?

Myeloma Debate: Is MRD Ready for Prime Time? - YesSee more

Myeloma Debate: Is MRD Ready for Prime Time? - Yes

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1See more

Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1

Multiple Myeloma: Minimal Residual DiseaseSee more

Multiple Myeloma: Minimal Residual Disease

Updates in CLL - 2023 Best of Hematology ConferenceSee more

Updates in CLL - 2023 Best of Hematology Conference

Measurable Residual Disease in Acute Myeloid Leukemia MRD in AMLSee more

Measurable Residual Disease in Acute Myeloid Leukemia MRD in AML

Events